Ordering Recommendation

Molecular testing to distinguish von Willebrand disease type 2N from hemophilia A.


Polymerase Chain Reaction/Sequencing




14-21 days

New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation

Lavender (EDTA), pink (K2EDTA) or yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature


Unacceptable Conditions

Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Reference Interval

By report

Interpretive Data

Background Information for von Willebrand Disease, Type 2N (VWF) Sequencing:
: Mucocutaneous bleeding after brushing or flossing teeth, unexplained bruising, prolonged repeated nosebleeds, menorrhagia, and prolonged bleeding following childbirth, trauma or surgery. Symptoms of type 2N are similar to mild hemophilia A.
Incidence: Approximately 1 in 100 to 1 in 1000 individuals.
Inheritance: Autosomal recessive.
Cause: Pathogenic VWF mutations.
Clinical Sensitivity: Unknown for VWD type 2N.
Methodology: Bidirectional sequencing of VWF exons 4, 9, 17, 18, 19, 20, 21, 24, 25, and 27 and the corresponding intron-exon boundaries.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations, deep intronic mutations, and large deletion/duplications will not be detected.  Mutations lying outside of VWF exons 4, 9, 17, 18, 19, 20, 21, 24, 25, and 27 will not be evaluated.

Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Hotline History
CPT Codes


Component Test Code* Component Chart Name LOINC
2005495 VWD Type 2N (VWF) Sequencing Specimen
2005496 VWD Type 2N (VWF) Sequencing Interp
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • VWD type 2N sequencing assay
  • VWF2N Sequencing
von Willebrand Disease, Type 2N (VWF) Sequencing